Zealand Pharma A Revenue Growth Rates (ZEAL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Zealand Pharma A  (NASDAQ: ZEAL)
 

ZEAL's Revenue Growth by Quarter and Year

Zealand Pharma A's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZEAL Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December 46.55
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 46.55

ZEALs Annual Revenue
Zealand Pharma A's Revenue in the fiscal year 2021 $ 292.57 millions
Zealand Pharma A's Revenue in the fiscal year 2020 $ 54.09 millions
Zealand Pharma A's Revenue in the fiscal year 2019 $ 6.20 millions
Zealand Pharma A's Revenue in the fiscal year 2018 $ 6.02 millions
Zealand Pharma A's Revenue in the fiscal year 2017 $ 27.17 millions




ZEAL Revenue fourth quarter 2021 Y/Y Growth Comment
Zealand Pharma A achieved in the fourth quarter 2021, above Company average Revenue surge of 424.19% year on year, to $ 46.55 millions.

Looking into fourth quarter 2021 results within Major Pharmaceutical Preparations industry 270 other companies have achieved higher Revenue growth. While Zealand Pharma A' s Revenue doubling of 424.19% ranks overall at the positon no. 4591 in the fourth quarter 2021.


ZEAL Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December 424.19 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   349.3 % - - -

Financial Statements
Zealand Pharma A's fourth quarter 2021 Revenue $ 46.55 millions ZEAL's Income Statement
Zealand Pharma A's fourth quarter 2020 Revenue $ 8.88 millions Quarterly ZEAL's Income Statement


ZEAL Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 500 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   349.3 % - - -


Back to ZEAL Growth rate Comparisons >> Back to ZEAL Growth rate Comparisons >>


Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #271
Healthcare Sector #667
Overall #4591

Revenue Y/Y Growth Statistics
High Average Low
772.63 % 284.66 % -77.84 %
(Dec 31 2020)   (Dec 31 2018)
Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #271
Healthcare Sector #667
Overall #4591
Revenue Y/Y Growth Statistics
High Average Low
772.63 % 284.66 % -77.84 %
(Dec 31 2020)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Zealand Pharma A's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ZEAL's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ZEAL's IV. Quarter Q/Q Revenue Comment


Zealand Pharma A's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Dec 31 2018)		 12 Months Ending
Cumulative Revenue 12 Months Ending $ 292.57 $ 54.09 $ 6.20 $ 6.02 $ 0.00
Y / Y Revenue Growth (TTM) 440.93 % 772.63 % 2.93 % -77.84 % -
Year on Year Revenue Growth Overall Ranking # 4591 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 440.93 % 772.63 % 2.93 % -77.84 % -
Seq. Revenue Growth (TTM) Overall Ranking # 4591 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Assuming the Zealand Pharma A's fiscal year would have ended in Dec 31 2021, Zealand Pharma A would have reprted above average annual Revenue surge of 440.93% year on year, of $ 293 millions.
This marks a slow-down of the companys growth trends and from the 772.63% surge in Dec 31 2020.

In the Healthcare sector 666 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4591.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 271
Healthcare Sector # 667
Overall # 4591

Revenue TTM Y/Y Growth Statistics
High Average Low
772.63 %
 284.66 %
-77.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 271
Sector # 667
S&P 500 # 4591
Cumulative Revenue growth Comment
Assuming the Zealand Pharma A's fiscal year would have ended in Dec 31 2021, Zealand Pharma A would have reprted above average annual Revenue surge of 440.93% year on year, of $ 293 millions.
This marks a slow-down of the companys growth trends and from the 772.63% surge in Dec 31 2020.

In the Healthcare sector 666 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4591.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 271
Healthcare Sector # 667
Overall # 4591

Revenue TTM Y/Y Growth Statistics
High Average Low
772.63 %
284.66 %
-77.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 271
Sector # 667
S&P 500 # 4591




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ZEAL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Dec 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2021
Cytokinetics Incorporated727.13%$ 727.135 millions
Theralink Technologies Inc 706.69%$ 706.691 millions
Clene Inc 586.21%$ 586.207 millions
Lftd Partners Inc 482.17%$ 482.174 millions
Cardiff Lexington Corporation465.13%$ 465.127 millions
Meiragtx Holdings Plc455.54%$ 455.536 millions
Lumos Pharma Inc 450.00%$ 450.000 millions
Biohaven Ltd 441.13%$ 441.132 millions
Nexgel Inc 427.72%$ 427.723 millions
Baudax Bio Inc 426.32%$ 426.316 millions
Molecular Templates Inc 413.70%$ 413.697 millions
Hyperion Defi inc 400.00%$ 400.000 millions
Sqz Biotechnologies Company396.58%$ 396.582 millions
Gain Therapeutics inc374.80%$ 374.802 millions
Inotiv Inc 370.85%$ 370.847 millions
Codiak Biosciences Inc 369.33%$ 369.329 millions
Aerie Pharmaceuticals Inc 364.55%$ 364.555 millions
Insight Molecular Diagnostics Inc 357.97%$ 357.968 millions
Palvella Therapeutics Inc 349.81%$ 349.814 millions
Liquidia Corporation334.68%$ 334.679 millions
Astrotech Corp331.54%$ 331.538 millions
Voyager Therapeutics Inc 329.48%$ 329.478 millions
Roivant Sciences Ltd 323.32%$ 323.322 millions
Arvinas Inc 316.91%$ 316.907 millions
Delcath Systems Inc 315.98%$ 315.976 millions
Cyclo Therapeutics Inc 301.90%$ 301.903 millions
Cyclerion Therapeutics Inc 300.00%$ 300.000 millions
Pfizer Inc297.43%$ 297.427 millions
Viridian Therapeutics Inc 296.30%$ 296.296 millions
Creative Medical Technology Holdings Inc 287.17%$ 287.166 millions


About Zealand Pharma A Revenue Growth Rates (ZEAL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Zealand Pharma A s (CIK 1674988).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-22-037611
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Zealand Pharma A s’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.